FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2 In pivotal trials, CAPLYTA® did not increase mean weight gain, metabolic changes, or reported sexual side effects1,2 In a six-month open-label extension safety study, safety profile was consistent with pivotal studies and 80% of MDD patients taking CAPLYTA® achieved response, with 65% of patients reaching remission from depression3 CAPLYTA® offers a new option for the 2 in 3 people who experience residual symptoms despite their current antidepressant treatment1,2,3Weiter zum vollständigen Artikel bei Johnson & Johnson Weiter zum vollständigen Artikel bei Johnson & Johnson